Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

PHASE4CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

Esomeprazole

Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate

DRUG

Placebo

once daily

Trial Locations (45)

Unknown

Research Site, Huntsville

Research Site, Tucson

Research Site, Little Rock

Research Site, Anaheim

Research Site, Burbank

Research Site, Castro Valley

Research Site, Orange

Research Site, San Diego

Research Site, Boynton Beach

Research Site, Coral Springs

Research Site, DeLand

Research Site, Hollywood

Research Site, Jupiter

Research Site, Pembroke Pines

Research Site, South Miami

Research Site, Tampa

Research Site, Zephyrhills

Research Site, Stockbridge

Research Site, Overland Park

Research Site, Lexington

Research Site, Hollywood

Research Site, Las Vegas

Research Site, Medford

Research Site, Perth Amboy

Research Site, West Orange

Research Site, Albuquerque

Research Site, Binghamton

Research Site, Huntersville

Research Site, Raleigh

Research Site, Winston-Salem

Research Site, Cincinnati

Research Site, Dayton

Research Site, Kettering

Research Site, Oklahoma City

Research Site, Chattanooga

Research Site, Johnson City

Research Site, Amarillo

Research Site, Fort Worth Dallas

Research Site, Houston

Research Site, Ogden

Research Site, Burke

Research Site, Christiansburg

Research Site, Fredericksburg

Research Site, Newport News

Research Site, Bellevue

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY